Thyrolytics
An easy-to-use lateral flow test that rapidly detects COVID-19 using saliva samples.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Acquisition | ||
| Total Funding | 000k | ||
| EUR | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (55 %) | 4603 % | (85 %) | (95 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (181 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (656 %) | (213 %) | (1831 %) | (565 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Thyrolytics operates in the healthcare diagnostics sector, specializing in therapeutic drug monitoring for biologic therapies. The company serves medical professionals and healthcare institutions, providing them with advanced diagnostic tools to optimize patient care. Thyrolytics' core product is a range of highly accurate, point-of-care tests, including the Viraspec COVID-19 Saliva Test Kit, which delivers results in 5-10 minutes without the need for nasal swabs or blood draws. The company ensures compliance with data protection regulations such as GDPR, safeguarding personal information meticulously. Thyrolytics generates revenue through the sale of its diagnostic kits and related services, targeting markets in the European Economic Area and beyond.
Keywords: diagnostic solutions, therapeutic drug monitoring, biologic therapies, autoimmune, oncology, neurology, COVID-19 test, point-of-care, GDPR compliance, healthcare diagnostics.